On September 11, 2015, the Board of Directors of International Stem Cell Corporation appointed Mahnaz Ebrahimi, age 58, as its new Chief Financial Officer effective September 14, 2015. Ms. Ebrahimi has been assisting the company on accounting and SEC reporting matters as a consultant for the last several months. She has more than 25 years of experience in senior level financial management, accounting and SEC reporting matters, having worked with various publicly traded and privately held biotechnology, life science, and technology companies in an employee or a consultant capacity.

Most recently, in addition to her consulting for the company, she has served as a consultant for Flux Power Holdings, assisting with the preparation of financial statements and periodic SEC reporting. Before that, she served as a consultant for Polaris Pharmaceuticals in 2014, where she was responsible for preparation of financial statements and for other accounting/finance activities, and Ocera Therapeutics in 2013, where she was heavily involved in and significantly contributed towards the successful completion of complex transactions.